Catalog No.
DHC12505
Description
Solanezumab is a humanized monoclonal IgG1 antibody directed against the mid-domain of the Aβ peptide. It recognizes soluble monomeric, not fibrillar, Aβ. Solanezumab (formerly known as LY2062430) is a monoclonal antibody being developed by Lilly as a potential therapy for people with mild cognitive impairment caused by Alzheimer’s disease.
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
AICD-57, A4, Beta-CTF, Protease nexin-II, Gamma-CTF(50), ABPP, S-APP-beta, APP, Abeta40, Abeta42, AID(59), Amyloid intracellular domain 59, AID(57), S-APP-alpha, Gamma-CTF(59), Beta-secretase C-terminal fragment, Amyloid-beta precursor protein, Amyloid precursor protein, Beta-APP42, PreA4, Alzheimer disease amyloid protein, APPI, PN-II, AICD-59, Alpha-secretase C-terminal fragment, Amyloid-beta A4 protein, Amyloid intracellular domain 57, CVAP, Amyloid intracellular domain 50, Beta-APP40, AD1, Cerebral vascular amyloid peptide, AID(50), Alpha-CTF, Gamma-CTF(57), AICD-50
Concentration
1.8 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P05067
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
LY2062430, CAS: 955085-14-0
Clone ID
Solanezumab
Note
For research use only. Not suitable for clinical or therapeutic use.
Avoid or Embrace? Practice Effects in Alzheimer's Disease Prevention Trials., PMID:35783127
Magnetic resonance imaging measures of brain volumes across the EXPEDITION trials in mild and moderate Alzheimer's disease dementia., PMID:35783453
The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report., PMID:35841240
Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease., PMID:36151869
Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates., PMID:36281062
Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease., PMID:36348972
Review of Alzheimer's disease drugs and their relationship with neuron-glia interaction., PMID:36593897
A combined physiologically-based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease., PMID:36632701
Investigational treatments for neurodegenerative diseases caused by inheritance of gene mutations: lessons from recent clinical trials., PMID:36751779
Targeting amyloid β in Alzheimer's disease: Meta-analysis of low-dose solanezumab in Alzheimer's disease with mild dementia studies., PMID:36946603
Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's disease., PMID:37017737
Mechanism Exploration of Amyloid-β-42 Disaggregation by Single-Chain Variable Fragments of Alzheimer's Disease Therapeutic Antibodies., PMID:37176076
APOE ε4's impact on response to amyloid therapies in early symptomatic Alzheimer's disease: Analyses from multiple clinical trials., PMID:37204338
Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force., PMID:37357282
Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis., PMID:37423541
Trial of Solanezumab in Preclinical Alzheimer's Disease., PMID:37458272
Comparative Study of Safety and Efficacy of Angiotensin-Receptor Blockers and Anti Amyloid-ß Monoclonal Antibodies for the Treatment of Alzheimer's Disease: A Systematic Review., PMID:37746412
Monoclonal Antibody Treatments for Alzheimer's Disease: Aducanumab and Lecanemab., PMID:39726673
Knowledge-guided Deep Temporal Clustering for Alzheimer's Disease Subtypes in Completed Clinical Trials., PMID:37873161
Patients with geriatric syndromes and anti-amyloid therapies: lack of consideration? An exploratory analysis of the literature., PMID:37881360
Navigating the dementia landscape: Biomarkers and emerging therapies., PMID:38215913
Development of amyloid beta-directed antibodies against Alzheimer's disease: Twists and turns., PMID:38220210
Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease., PMID:38400532
More failure with solanezumab - this time in preclinical Alzheimer's disease., PMID:38414336
Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis., PMID:38429615
Correction: Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N-truncted Abeta in sporadic Alzheimer disease cases and mouse models., PMID:38526686
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial., PMID:38683602
Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer's disease., PMID:38685682
Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials., PMID:38706272
Passive immunotherapy for Alzheimer's disease: challenges & future directions., PMID:38715084
Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities., PMID:38740836
A Review of Recent Advances in the Management of Alzheimer's Disease., PMID:38756263
Beyond lecanemab: Examining Phase III potential in Alzheimer's therapeutics., PMID:38868475
Engineered Antibodies to Improve Efficacy against Neurodegenerative Disorders., PMID:38928395
Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies., PMID:39044488
Characterizing Clinical Progression in Cognitively Unimpaired Older Individuals with Brain Amyloid: Results from the A4 Study., PMID:39044489
Longitudinal Phospho-tau217 Predicts Amyloid Positron Emission Tomography in Asymptomatic Alzheimer's Disease., PMID:39044490
Longitudinal Trajectories of the Cognitive Function Index in the A4 Study., PMID:39044492
Change in Digital Cognitive Test Performance between Solanezumab and Placebo Groups in Preclinical Alzheimer's Disease: Secondary Analyses from the A4 Study., PMID:39044493
Greater White Matter Hyperintensity Volume Is Associated with the Number of Microhemorrhages in Preclinical Alzheimer's Disease., PMID:39044495
Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician-patient engagement., PMID:39306695
Limitations and potential strategies of immune checkpoint blockade in age-related neurodegenerative disorders., PMID:39313800
Anti-amyloid β Antibody Therapies for Alzheimer's Disease: Association between the Target of Amyloid β Aggregates and the Clinical Efficacy of Anti-amyloid β Antibody., PMID:39401909
A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer's disease., PMID:39432414
Second-generation anti-amyloid monoclonal antibodies for Alzheimer's disease: current landscape and future perspectives., PMID:39865265
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial., PMID:39974075
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial., PMID:40120616
The Efficacy of Anti-amyloid Monoclonal Antibodies in Early Alzheimer's Dementia: A Systematic Review., PMID:40346804
Changes in Daily Functioning in Association With Tau and Amyloid Among Unimpaired Older Adults With and Without Elevated Amyloid., PMID:40440591
Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease., PMID:40459787
Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?, PMID: 24981190
Mutual population-shift driven antibody-peptide binding elucidated by molecular dynamics simulations, PMID: 31996730
Need for a trial of solanezumab in mild Alzheimer's disease, PMID: 26330409
Early Dementia Screening, PMID: 26838803
[Immunotherapy for Alzheimer's disease], PMID: 26815584
Recent trial shows that solanezumab has disease modifying effects, PMID: 26318507
Safety and biomarker effects of solanezumab in patients with Alzheimer's disease, PMID: 22672770
Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials, PMID: 28365320
Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease, PMID: 24716687
Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease, PMID: 24724181
Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease, PMID: 24716689
Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease, PMID: 24716688
Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab, PMID: 23302661
Anti-Aβ agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis, PMID: 33046560
Delayed-start analysis for demonstrating disease modification of solanezumab, PMID: 29854938
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease, PMID: 34155411
Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis, PMID: 31831056
Delayed-Start Analyses in the Phase 3 Solanezumab EXPEDITION3 Study in Mild Alzheimer's Disease, PMID: 29405226
Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models, PMID: 26467270
Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease, PMID: 22134132
A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS), PMID: 27019841
The Failure of Solanezumab - How the FDA Saved Taxpayers Billions, PMID: 28467878
Chemical and neuropathological analyses of an Alzheimer's disease patient treated with solanezumab, PMID: 27725918
Alzheimer disease: Solanezumab-prospects for meaningful interventions in AD?, PMID: 26526537
The preclinical Alzheimer cognitive composite: measuring amyloid-related decline, PMID: 24886908
Sixty seconds on . . . solanezumab, PMID: 27899350
Efficacy and safety of anti-amyloid- β immunotherapy for Alzheimer's disease: a systematic review and network meta-analysis, PMID: 29296624
Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years, PMID: 29854931
The Integrated Alzheimer's Disease Rating Scale (iADRS) Findings from the EXPEDITION3 Trial, PMID: 29616706
Quantile regression to characterize solanezumab effects in Alzheimer's disease trials, PMID: 29067306
Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials, PMID: 33321511
Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease, PMID: 27239538
Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β, PMID: 29686315
Molecular Docking and Dynamic Simulation of AZD3293 and Solanezumab Effects Against BACE1 to Treat Alzheimer's Disease, PMID: 29910719
The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset, PMID: 29037101
Passive antiamyloid immunotherapy for Alzheimer's disease, PMID: 32040044
Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies, PMID: 32989305
Pathways Connecting Late-Life Depression and Dementia, PMID: 32231570
Anti-amyloid-β protein agents for the treatment of Alzheimer's disease: an update on emerging drugs, PMID: 32772738
Solanezumab and the amyloid hypothesis for Alzheimer's disease, PMID: 28034844
Solanezumab: too late in mild Alzheimer's disease?, PMID: 28102152
Grasping at straws: the failure of solanezumab to modify mild Alzheimer's disease, PMID: 30376649
Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?, PMID: 23574434
Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia, PMID: 30511011
Solanezumab for the treatment of mild-to-moderate Alzheimer's disease, PMID: 22288451
The amyloid hypothesis of Alzheimer's disease at 25 years, PMID: 27025652
Solanezumab for Alzheimer's disease, PMID: 21504387
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease, PMID: 24450890
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients, PMID: 26238576
Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease, PMID: 29365294
For research use only. Not for human or drug use.
